Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity

ConclusionTargeting of CD39 by ASOs represents a promising state-of-the art therapeutic approach to improve immune responses against tumors.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research